BETHESDA, Md., Jan. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (NASDAQ: MITI) today announced that it will participate in the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11th - 14th in San Francisco. Christian Itin, Ph.D., Micromet's President and CEO, will present a 30 minute corporate overview on Thursday, January 14th at 12:30 PM PST. The presentation will be webcast live and may be accessed by visiting the Micromet website at http://www.micromet-inc.com/. A replay of the webcast will be available for 90 days. About Micromet, Inc. Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at http://www.micromet-inc.com/. DATASOURCE: Micromet, Inc. CONTACT: Jennifer Neiman, Micromet, Inc., Director, Corporate Communications, +1-240-235-0246, Web Site: http://www.micromet-inc.com/

Copyright